Hong Kong Construction Stock News

Flat Glass Group Co., Ltd. ( HKG:6865 ), might not be a large cap stock, but it saw a decent share price growth of 20...

Investors in China Hongqiao Group Limited ( HKG:1378 ) had a good week, as its shares rose 2.3% to close at HK$23.48...

It's been a good week for Jinxin Fertility Group Limited ( HKG:1951 ) shareholders, because the company has just...

China Petroleum & Chemical Corporation ( HKG:386 ) just released its latest half-yearly report and things are not...

As you might know, Shanghai Henlius Biotech, Inc. ( HKG:2696 ) recently reported its interim numbers. It was a...

Last week saw the newest half-year earnings release from China Resources Building Materials Technology Holdings Limited...

As of August 2026, Asian markets have been navigating a complex landscape marked by global economic uncertainties and fluctuating investor sentiment. Despite these challenges, opportunities for value investing persist, with certain stocks trading at a discount offering potential for growth in the long term. Identifying undervalued stocks involves looking for companies with strong fundamentals that remain resilient amid broader market volatility.

As global markets navigate a complex landscape marked by rising oil prices and geopolitical tensions, investors are increasingly turning their attention to opportunities in Asia. Penny stocks, though often seen as relics of past market eras, continue to capture interest due to their potential for growth and affordability. By focusing on companies with strong financial foundations, investors can uncover promising opportunities within this segment of the market.

Huaneng Power International (SEHK:902) reported half year 2026 results that showed lower revenue and net income compared with the same period in 2025. The earnings update appears to have influenced recent trading in the stock. See our latest analysis for Huaneng Power International. Since the earnings announcement on 18 August 2026, Huaneng Power International’s share price has been volatile, with the stock at HK$5.45 after a 1 day gain of 1.11% but a 90 day share price return that has fallen...

Investors in Xinyi Solar Holdings (SEHK:968) are assessing a fresh leadership shift after the company announced the retirement of executive director and financial controller Mr. Chu Charn Fai and the appointment of Mr. Lam Chi Kwong. See our latest analysis for Xinyi Solar Holdings. At a latest share price of HK$2.345, Xinyi Solar Holdings has seen a 1 month share price return of 11.14%, yet its year to date share price return is down 23.37% and the 5 year total shareholder return is down...

WuXi Biologics (Cayman) half year earnings in focus WuXi Biologics (Cayman) (SEHK:2269) reported half year 2026 earnings, noting higher sales, net income and earnings per share compared with the same period in 2025. See our latest analysis for WuXi Biologics (Cayman). Alongside these half year results, WuXi Biologics (Cayman) has seen strong recent momentum, with a 30 day share price return of 33.5% and a 90 day share price return of 54.99%, while the 1 year total shareholder return is...

HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed received approval from China’s National Medical Products Administration for an Investigational New Drug application linked to HBM7004, a bispecific antibody targeting advanced solid tumors. See our latest analysis for HBM Holdings. The HBM7004 IND approval arrives as HBM Holdings trades at HK$16.54, with a 30-day share price return of 32.21% and a 90-day share price return of 40.77%, while the 3-year total shareholder return is...

What ZhongAn’s Latest Half Year Earnings Tell You ZhongAn Online P & C Insurance (SEHK:6060) reported half year 2026 net income of CNY 1,549.96m, compared with CNY 667.57m a year earlier, with basic and diluted EPS at CNY 0.92 versus CNY 0.45. See our latest analysis for ZhongAn Online P & C Insurance. The earnings news arrives after a mixed share price run for ZhongAn Online P & C Insurance, with the 7 day share price return of 4.10% and 90 day share price return of 2.73% set against a year...

Mobvista entered this earnings season with a growth stock label and a rich 29.5x trailing P/E. However, the share price has slipped 1.7% over the past week and 23.7% over three months. The latest quarter explains some of that unease. Q2 2026 net income came in at US$12.5m on revenue of US$574.3m, well below the profit level implied by recent quarters and trailing earnings. For a digital advertising and mobile marketing business priced for strong growth, that kind of profit squeeze is the...

Haitian International Holdings stock has been under pressure, down about 9% over the past week even before investors fully digested the latest half year report. The headline from these earnings is a margin squeeze that is starting to bite. Net profit margin over the last year slipped to 17.8% from 19.1%, and trailing earnings have softened after several years of slower growth. For short term traders that hurts. For long term investors the bigger question now is whether a roughly 8x P/E and...

China Resources Pharmaceutical Group stock closed at HK$4.65, capping a choppy few months in which the share price slipped over 5% in the past week and almost 1% over the past quarter. The market is still treating the company like a low-growth laggard with a P/E of about 6x, even as trailing net income from continuing operations reached ¥9.62b and net profit margin edged up to 1.5%. For anyone looking beyond today’s tick-by-tick moves, this earnings release is really a story about valuation...

In August 2026, United Company RUSAL International reported past half-year results to June 30, 2026, with sales rising to US$8,338 million from US$7,520 million and net income improving to US$419 million from a net loss of US$87 million a year earlier. This shift from loss to profit, alongside the Board’s approval of IFRS interim financial statements and review of budget execution, signals a clear turnaround in the company’s reported operational performance. We will now examine how the move...

T.S. Lines entered this earnings season with a value label on its back and a stock that has climbed 47.5% over the past month. The latest half year numbers now test whether that discount story still holds up. The focus is profitability. Net income from continuing operations for the trailing twelve months sits at US$372.7m on revenue of US$1.3b, which leaves a thinner net margin than a year ago. The market reaction around HK$12.63 suggests investors see support in the low P/E; however, the...

Abbisko Cayman stock closed at HK$9.875 on Tuesday, capping a weak run with the shares down about 4% over the past week and about 8% over the past month. The market reaction looks chilly, yet the headline from these results is not the share price. It is the return to a deep loss in H1 2026, with basic earnings per share at a loss of C¥0.31 on C¥97.265 million of revenue, alongside ongoing multi year loss forecasts and a valuation that screens as inexpensive on book value. Is Abbisko Cayman...

Hangzhou Qiandaohu Xunlong Sci-tech stock came into these H1 2026 results after a steady run, with the share price up about 3.8% over the past week and 2.1% over the past month to HK$74.45. The headline from the release is not the top line. It is profitability. Net profit margin over the last year sat at 42.5%, lower than the 51.6% level a year earlier, while the stock still trades on roughly 19.7x P/E. That mix of strong earnings and pressure on margins is what shareholders now have to...

Shenzhen Dobot closed at HK$24.68 after earnings, capping a rough three months in which the stock fell about 26%. Yet the headline from this robotic automation specialist is not the share price slide. It is the widening loss that now sits against a rich valuation. For the first half of 2026, Shenzhen Dobot reported revenue of ¥316.3m but a net loss of ¥105.7m and basic earnings per share of a ¥0.24 loss. At the same time the stock still trades on a high price to sales multiple, while...

Binhai Investment stock has barely moved over the past month, yet the fresh half year numbers quietly sharpened the earnings story. The market is still pricing the utility on a trailing P/E of 5.7x, far below both peers and the wider Asian gas utilities industry, even as trailing 12 month earnings grew 21.1% and net profit margin edged up to 3.9%. For investors, the headline is simple: profitability is improving while the valuation still prices in a heavy discount. The rest of the report...

Jacobio Pharmaceuticals Group stock has been quietly grinding higher in recent months and closed at HK$6.0 on 25 August, yet the real shock today sits in the earnings line. The company swung from repeated losses to a H1 2026 net profit of C¥600.6 million, with basic earnings per share at C¥0.78, and that is the headline investors are trying to price. For a biotech that had been treated as a long duration story, the new reality is simple. Jacobio is now profitable on a trailing twelve month...

Jinmao Property Services stock has drifted over the past week, yet the real story today is not the share price. The real story is a profit engine that looks squeezed. Trailing net profit margin has dropped to 7.9% from 11.6% a year earlier, even though revenue over the latest half year sits close to the prior period. Investors are reacting to a property services business that still earns money but does so with less cushion. That compression in profitability is the emotional trigger for...